Los ntawm Cocer Peptides 
1 month ago
Tag nrho cov kab lus thiab cov ntaub ntawv ntawm cov khoom lag luam muab rau ntawm lub vev xaib no tsuas yog rau cov ntaub ntawv tshaj tawm kev tshaj tawm thiab cov hom phiaj kev kawm.
Cov khoom muab rau hauv lub vev xaib no yog npaj tshwj xeeb rau kev tshawb fawb hauv vitro. Kev tshawb fawb hauv vitro (Latin: * hauv iav *, lub ntsiab lus hauv iav) yog ua los ntawm tib neeg lub cev. Cov khoom no tsis yog tshuaj, tsis tau txais kev pom zoo los ntawm US Food and Drug Administration (FDA), thiab yuav tsum tsis txhob siv los tiv thaiv, kho, lossis kho txhua yam mob, kab mob, lossis mob. Nws raug txwv nruj raws li txoj cai los qhia cov khoom no rau hauv tib neeg lossis tsiaj lub cev hauv txhua daim ntawv.
Kev rog rog tau dhau los ua qhov teeb meem kev noj qab haus huv loj zuj zus thoob ntiaj teb, nrog rau ntau yam tsis zoo rau tib neeg lub cev noj qab haus huv, xws li ua rau cov kab mob plawv, ntshav qab zib, thiab lwm yam mob. Nyob rau hauv xyoo tas los no, cov tshuaj GLP-1 tau tshwm sim los ua ib txoj kev kho mob zoo hauv kev tswj kev rog.
Daim duab 1 Cov txheej txheem ua tau ntawm kev poob phaus los ntawm GLP-1. GI, plab hnyuv; GLP-1, Glucagon-zoo li peptide-1; GLP-1R, Glucagon-zoo li peptide-1 receptor.
Mechanism of Action of GLP-1 Drugs in Obesity Treatment
GLP-1 yog endogenous peptide secreted los ntawm L hlwb nyob rau hauv txoj hnyuv endocrine system. GLP-1 cov tshuaj, tseem hu ua GLP-1 receptor agonists (GLP-1 RAs), ua raws li cov teebmeem ntawm lub cev ntawm GLP-1 los ntawm kev ua kom lub GLP-1 receptor thiab nws cov kev taw qhia hauv qab, yog li ua rau muaj ntau yam teebmeem ntawm lub cev uas pab tswj qhov hnyav.
Txhawb nqa insulin secretion: GLP-1 RAs txhawb nqa cov tshuaj insulin tso tawm los ntawm pancreatic β hlwb hauv cov piam thaj-dependant. Thaum cov ntshav qabzib nce siab, GLP-1 RAs khi rau GLP-1 receptors nyob rau saum npoo ntawm pancreatic β hlwb, ua kom cov kab mob hauv lub cev los txhawb kev tsim cov tshuaj insulin thiab tso tawm, yog li txo qis cov ntshav qabzib. Stabilizing ntshav qabzib qib pab txo cov rog synthesis thiab khaws cia, tiv thaiv kev qab los noj mov thiab qhov hnyav nce los ntawm cov ntshav qabzib hloov pauv.
Kev tsis qab los noj mov: GLP-1 RAs ua rau lub hauv nruab nrab lub paj hlwb, tshwj xeeb tshaj yog cov cheeb tsam hauv lub hlwb cuam tshuam nrog kev noj qab haus huv, xws li hypothalamus. Los ntawm kev khi rau GLP-1 receptors nyob rau saum npoo ntawm hypothalamic neurons, lawv tswj cov kev tso tawm neuropeptide, xws li txo qis kev noj qab haus huv-stimulating peptides thiab ua rau kom muaj kev noj qab haus huv-suppressing peptides, yog li inducing lub siab ntawm fullness, txo cov zaub mov noj, thiab ua tiav kev tswj qhov hnyav.
Kev ncua lub plab zom mov: GLP-1 RAs qeeb tus nqi ntawm lub plab zom mov nkag mus rau hauv cov hnyuv me, ua rau lub sijhawm cov zaub mov tseem nyob hauv plab thiab ua kom muaj kev noj qab haus huv. Qhov kev ncua ntev ntawm lub plab khoob tsis yog tsuas yog txo cov pluas noj tab sis kuj ua kom cov ntshav qabzib nyob ruaj khov, tiv thaiv postprandial ntshav qabzib spikes thiab yog li txo cov rog.
Scheme 1 A schematic txheej txheem cej luam ntawm GLP-1 receptor agonists: kev faib tawm, kev nyab xeeb tshuaj, thiab kev ua tau zoo. GI, plab hnyuv; GLP-1R, Glucagon-zoo li peptide-1 receptor; PEG, Polyethylene glycol.
Kev siv cov tshuaj GLP-1 hauv kev kho mob rog
Kev kho cov neeg laus rog: Hauv kev kho cov neeg laus rog rog, GLP-1 RAs tau ua tiav cov txiaj ntsig tseem ceeb. Theem III kev soj ntsuam kev sim ntawm semaglutide tau ua tiav, nrog cov txiaj ntsig qhia qhov hnyav poob. Hauv KAUJ RUAM 2.4 mg / lub lim tiam semaglutide project, cov neeg mob tau ntsib kev poob ceeb thawj, ntxiv kev lees paub qhov ua tau zoo ntawm GLP-1 RAs hauv kev kho cov neeg laus rog. Cov tshuaj no feem ntau yog siv los ua ib feem ntawm qhov kev pabcuam yuag tag nrho, ua ke nrog kev tswj hwm kev noj haus thiab kev tawm dag zog ib nrab, kom ua tiav cov txiaj ntsig zoo dua.
Kev kho mob rog thaum yau: Cov kev tshawb fawb tsis ntev los no tau pom tias GLP-1 cov tshuaj xws li exenatide, semaglutide, thiab liraglutide tau siv los kho cov mob rog thaum menyuam yaus, xws li kev rog hnyav, rog rog txuam nrog polycystic zes qe menyuam syndrome (PCOS), thiab hypothalamic rog. Piv txwv li, cov kev tshawb fawb tau pom tias cov tshuaj no muaj qee yam cuam tshuam rau kev tswj qhov hnyav nce hauv cov menyuam yaus, pab txhim kho cov kab mob metabolic, thiab muab cov kev xaiv tshiab rau kev kho mob ntawm cov menyuam yaus rog rog.
Kev kho mob rog rog rau cov neeg tshwj xeeb - cov neeg mob PCOS: Polycystic ovary syndrome (PCOS) yog ib qho kab mob endocrine ntawm cov poj niam uas muaj hnub nyoog yug me nyuam, thiab kev rog rog muaj nyob rau hauv cov neeg mob PCOS. GLP-1 RAs muaj qhov tshwj xeeb zoo hauv kev kho kev rog rog hauv cov neeg mob PCOS. Cov kev tshawb fawb tau pom tias GLP-1 txoj kev kho tsis tsuas yog txo qhov hnyav hauv cov neeg mob PCOS nkaus xwb tab sis kuj tseem txhim kho cov tshuaj insulin, txo qis hyperandrogenism, thiab tseem ua rau muaj feem cuam tshuam txog kev xeeb tub thiab hauv vitro fertilization. Qhov no ua rau GLP-1 RAs yog qhov kev xaiv zoo tshaj plaws rau cov neeg mob PCOS rog rog, muab txoj hauv kev tshiab rau kev txhim kho lawv txoj kev noj qab haus huv thiab kev xeeb tub.
Xaus
Hauv cov ntsiab lus, GLP-1 cov tshuaj, uas yog lub zog tshiab hauv kev kho mob rog rog, ua kom pom cov ntawv thov kev cia siab hauv kev kho mob rog rog hauv cov neeg laus, menyuam yaus, thiab cov neeg tshwj xeeb (xws li cov neeg mob PCOS) vim lawv cov txheej txheem tshwj xeeb ntawm kev ua. Los ntawm ntau txoj hauv kev, suav nrog kev txhawb nqa cov tshuaj insulin secretion, txo qis qab los noj mov, thiab ncua kev ua pa hauv plab, GLP-1 RAs pab tau cov neeg mob txo qhov hnyav thiab txhim kho cov txheej txheem metabolic.
Hauv kev kho mob rau cov neeg laus, cov tshuaj xws li liraglutide thiab semaglutide tau raug lees paub los ntawm kev sim tshuaj, muab kev kho mob zoo rau cov neeg mob rog. Hauv kev kho mob rog rog hauv PCOS cov neeg mob, GLP-1 RAs tsis tsuas yog pab txo qhov hnyav xwb tab sis kuj tseem txhim kho cov kab mob endocrine cuam tshuam nrog tus mob, muab ntau yam txiaj ntsig rau cov neeg mob PCOS.
Qhov chaw
[1] Zhang D, Lu H. GLP-1RA: New Hope in Obesity Therapy [J]. Phau ntawv Journal of Biosciences and Medicines, 2025,13(2):465-479. https://cstj.cqvip.com/Qikan/Article/Detail?id=HS727602025002035
[2] Kavarian PN, Mosher TL, Haija MA E. Kev siv glucagon-zoo li-peptide 1 receptor agonist hauv kev kho mob ntawm menyuam yaus rog rog.[J]. Kev xav tam sim no hauv Pediatrics, 2024, 36 5: 542-546. https://api.semanticscholar.org/CorpusID: 272115519
[3] Wang JY, Wang QW, Yang XY, et al. GLP-1 receptor agonists rau kev kho mob rog: Lub luag hauj lwm raws li kev cog lus [J]. Frontiers hauv Endocrinology, 2023, 14: 1085799.DOI: 10.3389/fendo.2023.1085799.
[4] Pedrosa MR, Franco DR, Gieremek HW, et al. GLP-1 Agonist kho Kev rog rog thiab tiv thaiv kab mob plawv: Dab tsi tau ua tiav tam sim no?[J]. Daim Ntawv Qhia Txog Atherosclerosis tam sim no, 2022,24(11):867-884.DOI:10.1007/s11883-022-01062-2.
[5] Baranowska-Bik A. Kev kho cov rog rog hauv cov poj niam nrog PCOS siv GLP-1 analogues - cov txiaj ntsig thiab kev txwv [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia][J]. Endokrynologia Polska, 2022,73(3):627-643.DOI:10.5603/EP.a2022.0047.
